ReviewMedical oncology (Northwood, London, England)2025
Bisabolol as a natural anticancer agent: molecular insights and therapeutic potential in oncology.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of Plant-Derived Antioxidants in Oxidative Stress-Associated Myocardial Infarction: Structure-Activity Relationship (SAR)-Based Mechanistic Insights.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
α-Bisabolol is a naturally derived monocyclic sesquiterpene, abundantly present in German chamomile (Matricaria recutita) and various other aromatic plants and is also increasingly accessible via metabolic engineering platforms. The physicochemical profile and ADMET characteristics of α-bisabolol, suggest a high gastrointestinal absorption, and minimal P-glycoprotein and CYP450 interactions, which validate its drug-like potential. The multi-protein target engagement and predicted activity spectrum of α-bisabolol have been discussed in the manuscript by using in silico tools (SwissTargetPrediction and PASS), which aligns with the experimental anticancer results of α-bisabolol in leukemia, pancreatic, lung, and glioblastoma models. Mechanistically, the anticancer profile of α-bisabolol arises from the induction of mitochondrial apoptosis, disruption of PI3K/Akt/FAK/BRAF pathways, modulation of lipid-raft-associated Bid protein, and dysregulation of autophagy. The design and bioactivity of novel chemical derivatives (e.g., acyl, glycoside, and thiosemicarbazone analogs) and delivery systems (cyclodextrin inclusion complexes, PLGA nanoparticles), emphasizing improvements in solubility, potency, and systemic delivery have also been comprehensively discussed in this review. Finally, a critical evaluation of the clinical translation barriers including poor aqueous solubility, limited in vivo pharmacokinetics, CYP2C9/CYP2J-mediated metabolism, and formulation challenges of α-bisabolol have been succinctly provided. Overall, this review integrates phytochemistry, polypharmacology, mechanistic validation, and translational hurdles, thereby offering a novel roadmap for developing α-bisabolol as a viable anticancer therapeutic.
Indexed as
Identifiers
40974418What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.